Figure 3 shows the forest plot and pooled estimates of the effect of GLP-1 RAs (n = 2 placebo-controlled RCTs included using either liraglutide 1.8 mg/day or semaglutide at a dose of 0.1 mg, 0.2 mg or 0.4 mg/day subcutaneously) on histologic resolution of NASH with no worsening of liver fibrosis (panel A), and improvement in liver fibrosis stage without worsening of NASH (panel B). Here, GLP1R is linked to Hepatic fibrosis.